<DOC>
	<DOCNO>NCT02316509</DOCNO>
	<brief_summary>This open-label , dose-finding study SRN-927 administer orally continuous daily dose regimen PK lead-in period ( dose escalation period ) . The incidence dose limit toxicity ( DLT ) evaluate Day -7 first cycle ( 28 day ) treatment ( 35 day total ) . Depending safety tolerability , patient assign sequentially escalate dos SRN-927 use standard 3+3 design . All patient treat disease progression , unacceptable toxicity , patient withdrawal consent .</brief_summary>
	<brief_title>Study SRN-927 Postmenopausal Women With Locally Advanced Metastatic Estrogen Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Histologically cytologically proven diagnosis adenocarcinoma breast evidence either locally recurrent disease amenable resection radiation therapy curative intent , metastatic disease , progress least 6 month hormonal therapy ER+ breast cancer ERpositive , HER2negative No prior treatment ARN810 ( allow dose expansion stage ) No 2 prior chemotherapy advance metastatic setting At least 2 month must elapse use tamoxifen At least 6 month must elapse use fulvestrant At least 2 week must elapse use anticancer hormonal therapy At least 3 week must elapse use chemotherapy Females , 18 year age old Postmenopausal status define protocol Eastern Cooperative Oncology Group ( ECOG ) Performance status &lt; /= 2 Adequate organ function Untreated symptomatic brain metastasis Current treatment systemic anticancer therapy advance disease systemic experimental treatment another clinical trial Any follow within 12 month prior enrollment : myocardial infarction , severe/unstable angina , ongoing cardiac dysrhythmias Grade &gt; /= 2 , atrial fibrillation grade , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident include transient ischemic attack Active inflammatory bowel disease chronic diarrhea , short bowel syndrome , upper gastrointestinal surgery include gastric resection Known human immunodeficiency virus infection Major surgery within 4 week prior enrollment Radiation therapy within 2 week prior enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>